Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, PA, USA.
J Hepatol. 2012 Apr;56(4):795-802. doi: 10.1016/j.jhep.2011.11.012. Epub 2011 Dec 13.
BACKGROUND & AIMS: Hepatitis B e antigen (HBeAg) seroconversion is an important clinical and virological "landmark" during chronic hepatitis B virus (HBV) infection. Mutant viruses carrying the precore G1896A and/or the basal core promoter (BCP) A1762T/G1764A mutations are associated with HBeAg seroconversion. However, the exact role of these mutants in HBeAg seroconversion remains unclear, partly because the evolution of these mutant viruses before and after seroconversion has not been well studied.
Using our novel mutant quantification methods, the percentage of the mutant viruses was analyzed both cross-sectionally and longitudinally, before and after seroconversion.
Cross-sectional analysis showed that the percentage of both precore and BCP mutants gradually increased with age in the HBeAg-positive population. Follow-up of 18 HBeAg-positive patients revealed that the mutant percentage may stay low and stable for many years, followed by a steady increase in the percentage of G1896A and/or A1762T/G1764A mutants, from <10% to 50-100%, within about 3 years prior to seroconversion. In all cases, increase of mutant percentage was preceded or accompanied by elevated serum alanine aminotransferase. After the seroconversion, the mutant percentage could remain high or decrease significantly, sometimes to below 20%.
Levels of G1896A and A1762T/G1764A mutants (of genotypes B and C) in the HBeAg-positive patients may predict the time of HBeAg seroconversion. The dominance of these mutants in the HBeAg-positive phase is more likely the result of immune selection rather than the enhanced replication capability of the mutants. However, anti-HBe antibody may not be a major selection force for these mutants.
乙型肝炎 e 抗原(HBeAg)血清学转换是慢性乙型肝炎病毒(HBV)感染过程中的一个重要临床和病毒学“里程碑”。携带前 C 区 G1896A 和/或基本核心启动子(BCP)A1762T/G1764A 突变的变异病毒与 HBeAg 血清学转换相关。然而,这些突变体在 HBeAg 血清学转换中的确切作用仍不清楚,部分原因是血清学转换前后这些突变病毒的演变尚未得到很好的研究。
使用我们新的突变定量方法,在 HBeAg 阳性人群中进行了横断面和纵向分析,分别在血清学转换前后进行了分析。
横断面分析显示,在 HBeAg 阳性人群中,前 C 区和 BCP 区突变体的百分比随年龄逐渐增加。对 18 例 HBeAg 阳性患者的随访显示,突变体百分比可能多年来保持较低且稳定,随后 G1896A 和/或 A1762T/G1764A 突变体的百分比会逐渐增加,大约在血清学转换前 3 年内从<10%增加到 50-100%。在所有情况下,突变体百分比的增加都先于或伴随着血清丙氨酸氨基转移酶的升高。血清学转换后,突变体百分比可能保持较高或显著下降,有时降至<20%。
HBeAg 阳性患者中 G1896A 和 A1762T/G1764A 突变体(基因型 B 和 C)的水平可能预测 HBeAg 血清学转换的时间。在 HBeAg 阳性期这些突变体的优势更可能是免疫选择的结果,而不是突变体增强的复制能力。然而,抗-HBe 抗体可能不是这些突变体的主要选择力。